List of Excipients in Branded Drug FINTEPLA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
UCB Inc	FINTEPLA	fenfluramine	43376-322	ANHYDROUS CITRIC ACID	2038-12-29
UCB Inc	FINTEPLA	fenfluramine	43376-322	ETHYLPARABEN	2038-12-29
UCB Inc	FINTEPLA	fenfluramine	43376-322	HYDROXYETHYL CELLULOSE	2038-12-29
UCB Inc	FINTEPLA	fenfluramine	43376-322	METHYLPARABEN	2038-12-29
UCB Inc	FINTEPLA	fenfluramine	43376-322	POTASSIUM CITRATE	2038-12-29

FINTEPLA Excipient Strategy, Formulation IP, and Commercial Opportunities

Last updated: October 3, 2026

FINTEPLA is a 2.2 mg/mL oral solution of fenfluramine hydrochloride supplied by UCB for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. Its excipient system is commercially important because the product is pediatric, chronic-use, weight-based, orally administered, and subject to controlled-substance and REMS requirements. The strongest opportunities are in taste masking, preservative alternatives, dose-measurement systems, stability improvement, global reformulation, and differentiated delivery formats rather than simple excipient substitution.

What is FINTEPLA and how is it regulated?

FINTEPLA is an FDA-approved fenfluramine oral solution marketed under NDA 212102. The product contains 2.2 mg of fenfluramine hydrochloride per mL, equivalent to 2.2 mg of fenfluramine base per mL according to the prescribing information. It is administered orally using calibrated syringes and is titrated according to patient response and tolerability.

Regulatory attribute	FINTEPLA status
Active ingredient	Fenfluramine hydrochloride
Dosage form	Oral solution
Strength	2.2 mg/mL
FDA application	NDA 212102
Initial FDA approval	June 25, 2020
Initial indication	Seizures associated with Dravet syndrome
Second FDA indication	Seizures associated with Lennox-Gastaut syndrome
Second approval	March 25, 2022
Applicant and marketer	UCB, following acquisition of Zogenix
Controlled substance	Schedule IV
Risk controls	FINTEPLA REMS and echocardiographic monitoring
Primary patient population	Pediatric and adult patients with rare epileptic encephalopathies

The product’s regulatory profile affects excipient strategy. Any reformulation must preserve dose accuracy, palatability, chemical stability, microbiological quality, and the safety profile evaluated under the NDA. A material change to the excipient system can require FDA comparability data, stability studies, analytical bridging, and potentially clinical acceptability work.

What excipients are used in FINTEPLA oral solution?

The FDA prescribing information identifies the following inactive ingredients for FINTEPLA oral solution:

Excipient	Likely formulation function
Citric acid anhydrous	Acidulant and pH adjustment
Disodium phosphate anhydrous	Buffer component
Hydroxyethylcellulose	Viscosity modifier and suspension or solution-body agent
Methylparaben	Preservative
Potassium citrate monohydrate	Buffering and pH control
Sucralose	High-intensity sweetener
Strawberry flavor	Flavor masking
Purified water	Vehicle

The formulation is a water-based, flavored, sweetened oral liquid with a preservative system. Hydroxyethylcellulose improves mouthfeel and may support consistent dosing by controlling liquid rheology. The citrate and phosphate components provide pH control, which affects fenfluramine stability, preservative performance, flavor perception, and packaging compatibility.

The excipient architecture is conventional, but the commercial requirements are demanding. Fenfluramine is administered chronically to children, often at multiple dose levels and with dose escalation. The formulation must remain acceptable across repeated exposure while allowing caregivers to measure small volumes accurately.

How does the FINTEPLA excipient system support pediatric use?

Pediatric epilepsy products have three formulation priorities: palatability, dose flexibility, and administration reliability.

Sucralose and strawberry flavor reduce the sensory burden associated with repeated dosing. The use of a liquid eliminates the need for tablet swallowing and permits weight-based titration. Hydroxyethylcellulose can improve mouthfeel and reduce an excessively watery sensory profile, although higher viscosity can increase residual liquid in oral syringes and complicate dose transfer.

The principal excipient risks are:

1. Flavor fatigue during long-term therapy.
2. Variable acceptance among children with sensory sensitivities.
3. Preservative intolerance or parental preference for preservative-free products.
4. Inaccurate dosing caused by syringe handling, air bubbles, or residual liquid.
5. Stability changes after opening and during repeated household use.
6. Compatibility problems with feeding tubes or administration devices.

A commercially useful reformulation would need to improve one or more of these attributes without increasing dose variability or creating a new regulatory burden.

What formulation patents protect FINTEPLA?

The core commercial protection for FINTEPLA is expected to center on fenfluramine therapeutic-use claims, regulatory exclusivity, and product-specific intellectual property rather than broad ownership of common excipients such as purified water, citrate buffers, sucralose, or methylparaben.

The FDA Orange Book identifies patent and exclusivity information associated with NDA 212102. The relevant protection categories include:

Protection category	Commercial effect
Method-of-use patents	May delay or limit approval of abbreviated new drug applications for patented indications
Drug-product or formulation claims	May cover the oral solution composition, concentration, stability, or dosage form
Orphan-drug exclusivity	Blocks approval of the same drug for the same rare-disease indication during the exclusivity period
Pediatric exclusivity	Can add six months to qualifying patents and exclusivities
REMS requirements	Increase operational barriers for generic or follow-on manufacturers
Controlled-substance controls	Add manufacturing, distribution, inventory, and compliance obligations

An excipient substitution does not automatically avoid an Orange Book patent. A patent claim may cover a method of treatment, concentration range, dosage regimen, or pharmaceutical composition broadly enough to capture a reformulated product. Conversely, a generic manufacturer may be able to use a different flavor, preservative, or viscosity modifier if the change does not infringe the relevant claims and the product satisfies FDA sameness requirements.

Patent analysis should separate three questions:

• Whether an excipient is expressly recited in a patent claim.
• Whether the excipient is necessary to practice a broader composition claim.
• Whether the same therapeutic-use claims apply regardless of formulation.

For FINTEPLA, method-of-use claims and orphan-drug exclusivity may present a greater near-term barrier than the listed excipient combination itself. A commercial excipient supplier should not assume that supplying a nonidentical flavor or preservative creates freedom to operate for a finished product.

When does FINTEPLA lose exclusivity?

FINTEPLA has indication-specific orphan-drug exclusivity.

Milestone	Date or period
Dravet syndrome approval	June 25, 2020
Approximate seven-year orphan exclusivity period for Dravet syndrome	Through June 2027
Lennox-Gastaut syndrome approval	March 25, 2022
Approximate seven-year orphan exclusivity period for Lennox-Gastaut syndrome	Through March 2029
Potential pediatric exclusivity	May extend applicable FDA protections by six months if granted

Orphan-drug exclusivity is indication-specific. It does not necessarily prevent all fenfluramine products for all indications. A competing manufacturer could face different barriers depending on whether it seeks approval for Dravet syndrome, Lennox-Gastaut syndrome, another seizure disorder, or a non-epilepsy use.

Patent expiration dates may extend beyond orphan exclusivity. A generic launch assessment therefore must review the live Orange Book record, issued patents, terminal disclaimers, pediatric extensions, litigation outcomes, and any settlement restrictions. A formulation change alone does not eliminate method-of-use or product-patent risk.

What generic entry risks exist for FINTEPLA?

Generic entry is more complex than a conventional immediate-release tablet because FINTEPLA is a flavored oral solution with a controlled active ingredient and a restricted safety program.

A generic applicant would likely need to address:

• Pharmaceutical equivalence to the reference oral solution.
• Same active ingredient, strength, dosage form, and route.
• Inactive-ingredient safety and compatibility.
• Dose-delivery accuracy using an approved measuring device.
• Stability after opening.
• Microbiological quality during repeated use.
• Controlled-substance manufacturing and distribution controls.
• REMS or REMS-equivalence obligations.
• Paragraph IV certifications for listed patents.
• Labeling restrictions for patented indications.

A generic could seek a different flavor, preservative, buffer, or rheology modifier if the formulation remains pharmaceutically equivalent and acceptable to FDA. The commercial challenge is that pediatric patients and caregivers may resist switching from a familiar product, particularly when taste or syringe performance changes.

Potential launch scenarios include:

Scenario	Commercial consequence
Full-label generic after patent and exclusivity clearance	Highest substitution potential
Generic with one indication carved out	Limited pharmacy substitution and narrower market
Authorized generic or licensed product	Lower litigation exposure but possible price erosion
Alternative oral solution with a new concentration	Requires regulatory strategy and may not substitute automatically
Compounded fenfluramine preparation	Limited role because of quality, dosing, controlled-substance, and indication constraints

What commercial opportunities exist in FINTEPLA excipients?

Taste-masking systems

Taste is the most direct excipient opportunity. A new flavor platform could target lower sweetness, reduced aftertaste, natural flavor positioning, or improved acceptance among older children and adults. Candidate systems may include fruit flavors, flavor modulators, bitterness suppressors, and optimized acid-sweetener ratios.

The opportunity is commercially strongest if the system improves adherence without changing fenfluramine exposure or requiring a new concentration.

Preservative-free or low-preservative formulations

Methylparaben provides antimicrobial protection, but a preservative-free product could appeal to caregivers concerned about chronic exposure or sensitivity. Such a product would require a different microbiological control strategy, potentially including unit-dose packaging, aseptic filling, sterile or low-bioburden manufacturing, or a redesigned container-closure system.

This is a higher-cost opportunity. The business case depends on whether the market will pay for improved positioning and whether the formulation can maintain acceptable in-use stability.

Improved dose-delivery systems

A coordinated excipient and device strategy could reduce dosing errors. Opportunities include low-residual-volume syringes, bottle adapters, oral dosing cups for larger doses, and packaging that reduces foaming or air entrapment.

The device is not an excipient, but it directly affects the commercial performance of the formulation. A proprietary dosing system can create differentiation even when the liquid composition is difficult to protect broadly.

Alternate concentrations

A higher-concentration oral solution could reduce administration volume for older children and adults. A lower-concentration version could improve accuracy for very small pediatric doses. Concentration changes create regulatory and medication-error risks, especially when multiple strengths coexist.

A new concentration may have greater commercial value in international markets where dosing practices, syringe availability, and reimbursement rules differ.

Feeding-tube compatibility

Some patients with severe developmental or epileptic disorders receive medication through enteral feeding tubes. A formulation optimized for tube passage, low sorption, low clogging risk, and reliable dose recovery could support hospital and long-term-care use.

This opportunity requires evidence on adsorption, flushing volume, tube materials, administration sequence, and recovery after dilution.

How does FINTEPLA compare with competing epilepsy medicines?

Product	Active ingredient	Form	Excipient opportunity
FINTEPLA	Fenfluramine	Flavored oral solution	Taste, preservative, dosing device, tube compatibility
Epidiolex	Cannabidiol	Oral solution	Flavor, oil-solubilization, dose-volume optimization
Diacomit	Stiripentol	Capsule and powder for suspension	Pediatric suspension, palatability, dispersibility
Clobazam products	Clobazam	Tablets and oral suspension	Taste masking and low-dose accuracy
Valproate products	Valproate or divalproex	Multiple oral and solid forms	GI tolerability, liquid dosing, unit-dose formats

FINTEPLA has a differentiated commercial position because it is a purpose-designed liquid for rare developmental epileptic encephalopathies. Epidiolex is the closest high-profile liquid competitor in epilepsy, but its active ingredient, dosing, safety monitoring, and excipient requirements differ. The strongest excipient suppliers will develop platforms applicable across multiple pediatric neurology products rather than a single-product solution.

What manufacturing and IP barriers affect excipient suppliers?

Manufacturing barriers include reproducible hydroxyethylcellulose hydration, preservative uniformity, flavor consistency, low-bioburden processing, container-closure compatibility, and controlled-substance handling. Fenfluramine manufacturing and distribution also require compliance with Drug Enforcement Administration requirements.

IP barriers may arise from:

• Composition claims covering specific excipient combinations.
• Stability claims covering pH, concentration, or storage conditions.
• Device claims covering dose delivery.
• Method-of-use claims covering seizure indications.
• Trade secrets concerning flavor ratios, process parameters, or packaging.

Excipient suppliers should focus on platform claims that cover functional performance rather than a single named ingredient. Examples include bitterness suppression at defined fenfluramine concentrations, low-residual-volume delivery, preservative-free multidose stability, and enteral-tube compatibility.

What is the commercial outlook for FINTEPLA excipient innovation?

FINTEPLA’s commercial opportunity is concentrated in lifecycle management rather than commodity excipient replacement. UCB can preserve differentiation through improved taste, a new presentation, a device-linked product, or a formulation tailored to global markets.

The most attractive opportunities rank as follows:

1. Taste and aftertaste improvement with minimal regulatory change.
2. Dose-delivery systems that reduce caregiver error.
3. Feeding-tube-compatible packaging and administration.
4. Higher-concentration or lower-volume presentations.
5. Preservative-free unit-dose formats.
6. Global-market reformulations using locally accepted excipients and flavors.

The weakest opportunity is an unprotected substitution of one standard buffer or sweetener for another. That approach may reduce cost but is unlikely to create durable market differentiation unless it solves a documented stability, safety, or supply problem.

Key Takeaways

• FINTEPLA is a 2.2 mg/mL fenfluramine oral solution approved under NDA 212102.
• Its listed excipients are citric acid, disodium phosphate, hydroxyethylcellulose, methylparaben, potassium citrate, sucralose, strawberry flavor, and purified water.
• Pediatric palatability, dose accuracy, in-use stability, and controlled-substance compliance drive formulation strategy.
• Orphan-drug exclusivity is indication-specific and approximately extends through 2027 for Dravet syndrome and 2029 for Lennox-Gastaut syndrome, subject to applicable extensions and other protections.
• Method-of-use patents and regulatory exclusivity may create greater entry barriers than the individual excipients.
• The strongest commercial opportunities are taste masking, delivery devices, tube compatibility, concentration optimization, and preservative-free packaging.
• A generic manufacturer may use different excipients, but it must address pharmaceutical equivalence, inactive-ingredient safety, device performance, REMS obligations, and patent certifications.
• Excipient suppliers should pursue functional, platform-based IP and avoid relying on ownership of conventional ingredients.

FAQs

Can a generic FINTEPLA product use a different flavor?

Yes. A generic may use a different flavor if the product meets FDA requirements for pharmaceutical equivalence, inactive-ingredient safety, stability, labeling, and dosage performance. The change does not by itself avoid method-of-use or broader formulation patents.

Is methylparaben essential to FINTEPLA?

Methylparaben is the listed preservative, but it is not necessarily irreplaceable. A reformulated product could use another preservative system or unit-dose packaging, subject to stability, microbiological, safety, and regulatory requirements.

Could a higher-strength FINTEPLA solution reduce patent risk?

Not automatically. A higher-strength product may require a separate regulatory pathway and could still fall within therapeutic-use or broad composition claims. Concentration changes must be assessed against the full patent and exclusivity record.

Does FINTEPLA have biosimilar competition?

No. FINTEPLA contains a chemically synthesized small-molecule active ingredient, fenfluramine hydrochloride. The relevant competitive threat is generic or authorized-generic entry, not biosimilar substitution.

Which excipient innovation is most likely to support a premium product?

A formulation that improves pediatric acceptance and dose reliability is the strongest premium opportunity. Taste masking combined with a low-residual-volume syringe or feeding-tube-compatible package has more commercial value than an isolated change to a conventional buffer.

References

1. U.S. Food and Drug Administration. (2024). FINTEPLA (fenfluramine) oral solution prescribing information.
2. U.S. Food and Drug Administration. (2020). FDA approves treatment for seizures associated with Dravet syndrome.
3. U.S. Food and Drug Administration. (2022). FDA approves new treatment for seizures associated with Lennox-Gastaut syndrome.
4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
5. UCB. (2024). Annual report and financial results.
6. Drug Enforcement Administration. (2024). Controlled substances schedules.